Emerging Protective Actions of PGC-1α in Diabetic Nephropathy

Yuqing She,1,2 Mei Yu,1 Liang Wang,1 Yajing Wang,3 Penghua Fang,1 and Zhenwen Zhang3

1Key Laboratory for Metabolic Diseases in Chinese Medicine, Nanjing University of Chinese Medicine, Nanjing 210023, China
2Department of Endocrinology, Pukou Branch of Jiangsu People’s Hospital, Nanjing 211899, China
3Department of Endocrinology, Clinical Medical College, Yangzhou University, Yangzhou 225001, China

Correspondence should be addressed to Penghua Fang; hlcollegesci@sina.cn and Zhenwen Zhang; zwzhang@yzu.edu.cn

Received 19 July 2022; Revised 14 September 2022; Accepted 26 September 2022; Published 10 October 2022

Copyright © 2022 Yuqing She et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Renal impairment is affected by various mechanisms of oxidative stress, mitochondrial dysfunction, and basement membrane thickening, which are the major causes of renal dysfunction in diabetes. Of note, hyperglycemia-induced mitochondrial dysfunction has been identified as a common cause of diabetic nephropathy and renal impairment, and the decrease in PGC-1α expression brought on by hyperglycemia plays an immensurable role in both the reduction of mitochondrial biogenesis and the rise in oxidative stress. Reduced PGC-1α expression levels may occur with rising SGLT2-dependent increase of cytoplasmic sodium and protons in the renal cells of diabetes, even if the precise mechanism of hyperglycemia-induced disruption of PGC-1α expression has not been identified. Additionally, it has been observed that SGLT2 inhibitors enhance PGC-1α expression and activity and decrease cytoplasmic sodium and protons in many kidney cells, which may be helpful in reducing renal impairment brought on by diabetes. This review summarizes our and other recent studies on the function of PGC-1α in diabetic nephropathy, provides another potential mediator of the lower PGC-1α expression levels brought on by hyperglycemia in diabetics, and identifies a new pathogenesis of diabetes-related renal impairment. It also explains the mechanism underlying the protective effects of SGLT2 inhibitors on diabetic nephropathy. Therefore, it should be taken into account that SGLT2 inhibitors are an effective therapeutic strategy for reducing renal dysfunction caused by diabetes.

1. Introduction

In recent decades, diabetes mellitus (DM) has become a significant healthcare problem of aging, affecting millions of people all over the world [1]. DM affects every cell in the body, which explains the broad range of complications, including accelerated cardiac failure and renal impairment [2]. Diabetic nephropathy is manifested by tubular, interstitial, and arteriolar lesions and abnormalities [3]. Renal impairment is affected by various mechanisms of oxidative stress, mitochondrial dysfunction, and basement membrane thickening, which are the major causes of renal dysfunction in diabetes [4–6]. Notably, diabetic nephropathy and renal impairment have been linked frequently to hyperglycemia-induced mitochondrial dysfunction [6, 7]. There are numerous ways in which modifications might alter the structure and function of mitochondria, including changes to the membrane’s integrity, the generation of ROS, the number of mitochondria, and the process of biogenesis [6, 7].

A growing body of research has shown that the reduction in PGC-1α expression that leads to abnormalities in mitochondrial biogenesis and ROS generation is directly related to the hyperglycemia-induced mitochondrial dysfunction [8–10]. Numerous studies have shown that diabetes decreases PGC-1α expression and activity [10–12]. Additionally, podocytes and renal tubular cells may express less PGC-1α when hyperglycemia is present [13–15]. As a result, diabetic patients’ renal tubular cells and podocytes have decreased mitochondrial biogenesis and ATP production [13–15]. In return, the elevation of PGC-1α expression could promote the mitochondrial biogenesis and ATP production in the renal tubular cells and podocytes of diabetic patients [13–15]. These findings imply that the pathological progression of diabetic nephropathy may be greatly influenced by
the reduction of PGC-1α expression brought on by hyperglycemia.

This narrative review provides a new mediator of the decreased PGC-1α expression levels brought on by hyperglycemia, summarizes our research and that of other recent researchers regarding the function of PGC-1α in diabetic nephropathy, and establishes a novel pathogenesis for renal impairment brought on by diabetes.

2. The Effect of Oxidative Stress on Renal Impairment and PGC-1α Expression

Chronic oxidative stress, which mainly impacts the endocrine and immunological systems, leads to disturbed metabolic homeostasis, which results in the development of diabetes. Subsequent overproduction of reactive oxygen and proinflammatory factors creates a vicious circle in which persistent low-grade systemic inflammation and chronic oxidative stress interact. The development of diabetes-related renal impairment is accompanied by an increase in reactive oxygen, which alters mitochondrial activity and biogenesis in diverse kidney cells [6, 7]. A damaging feedback loop might be created by changes in mitochondrial homeostasis, which would worsen the damage to the kidney's tubular, podocyte, and mesangial cells [6, 7].

Although the exact mechanism of oxidative stress-induced diabetes-associated renal impairment has not been fully analyzed, decreased PGC-1α expression may be linked to decreased mitochondrial biogenesis as well as increased oxidative stress, which may exacerbate oxidative stress-induced diabetes-associated renal impairment [13–15]. PGC-1α has been connected to thermogenesis and the control of energy metabolism since it was initially discovered as a PPAR-interacting protein in brown adipose tissue [16]. Following that, research has shown that PGC-1α enhances both mitochondrial biogenesis and glucose metabolism [17–21]. In fact, PGC-1α is a master regulator of mitochondrial biogenesis, coordinating the transcriptional machinery to increase mitochondrial mass, enabling tissue response to rising energetic demands [17–20].

Numerous studies have shown that kidney dysfunction caused by PGC-1α deficiency accelerates oxidative stress and causes kidney dysfunction [21, 22]. First, reduced PGC-1α expression in the kidneys of diabetic rats has been linked to excessive ROS generation by defective mitochondria [23]. Second, PGC-1α has been shown to protect against oxidative stress [21, 22]. According to numerous reports, PGC-1α regulates ROS-scavenging enzymes, including the mitochondrial proteins manganese superoxide dismutase 1 and 2 [22–24]. Besides, PGC-1α, which can boost mitochondrial electron activity, has been described as a regulator of ROS metabolism by St-Pierre et al. [22]. Notably, PGC-1α overexpression lowers ROS production and increases mitochondrial number, biogenesis, and ATP production [21, 23]. In contrast, PGC-1α depletion by siRNAs prevents the upregulation of SOD1 and SOD2, as well as glutathione peroxidase 1 (GPX1), another ROS-scavenging enzyme, indicating that PGC-1α regulates cytoprotective responses under oxidative stress [22, 25]. Furthermore, PGC-1α expression rises in parallel with antioxidant defenses when mouse embryonic fibroblasts are exposed to H2O2, but PGC-1α knockdown suppresses the rise in ROS detoxifying genes in response to H2O2 [22]. Additionally, a number of studies have suggested that pharmacological PGC-1α activation could guard against mitochondrial malfunction and oxidative stress [26–28]. For instance, injection of resveratrol reduced oxidative stress and mitochondrial dysfunction in mouse models of diabetes through the activation of the AMPK/SIRT1/PGC-1α axis [26–28].

Taken together, PGC-1α can serve as a master regulator of oxidative stress and mitochondrial biogenesis, thus acting as a key regulator of ROS primarily generated by mitochondria.

3. The Protective Role of PGC-1α in Diabetes-Associated Renal Impairment

3.1. Hyperglycemia Inhibits PGC-1α Expression in the Kidney. It is well known that PGC-1α expression in the kidney is directly influenced by diabetes and experimentally induced hyperglycemia [11–15, 23]. Patients with diabetic nephropathy had lower levels of PGC-1α gene expression in their kidney tissue when they were examined in a clinical context [15]. Hyperglycemia-induced PGC-1α downregulation has been seen in animal models of diabetic nephropathy. Previous research has demonstrated that diabetic mice and rats have significantly lower levels of PGC-1α expression in their kidneys [11–14, 23, 29–32]. Low PGC-1α levels were subsequently linked to impaired renal function, glomerulosclerosis, and renal ectopic lipid deposition [23]. Additionally, the podocyte-specific PGC-1α knockout animals showed lower mtDNA stability and transcription as well as altered mitochondrial biogenesis machinery and mitochondrial fusion-fission apparatus [33].

In addition to studies conducted in animals, high glucose (HG) significantly decreased PGC-1α expression in HK-2 cells and podocytes in vitro [15, 29–31]. Consistently, a high (HG, 25 mM) concentration of glucose medium for 48 hours or 7 days caused a significant drop in PGC-1α levels in mesangial cells [23, 32, 33]. Functionally, HK-2 and mesangial cells as well as podocytes showed increased mitochondrial dysfunction and ROS formation in response to high glucose-induced reduced PGC-1α [15, 23, 33]. Taken together, these findings suggest that podocytes, tubular cells, and mesangial cells all exhibit hyperglycemia-induced downregulation of PGC-1α, which appears to be a common characteristic of diabetic nephropathy and plays a significant pathophysiological role in diabetes-related renal impairment.

On the other hand, PGC-1α overexpression or maintenance of PGC-1α expression and activity by its activators (resveratrol, PGRN, berberine, Rap1, Tug1, and pyruvate kinase M2) ameliorated renal function deterioration and glomerulosclerosis and decreased mitochondrial ROS generation in tubular and mesangial cells as well as podocytes in vitro and in vivo [23, 29, 34–40]. These findings support the hypothesis that PGC-1α may serve as a possible nephroprotective target in renal impairment caused by diabetes.
3.2. The Mechanisms of Hyperglycemia-Induced Low PGC-1α Expression

3.2.1. The Alteration of AMPK/SIRT1 Pathway under Hyperglycemic Conditions. It has been reported that downregulation of PGC-1α protein levels and activity in diabetes has been assumed to be a significant cause or consequence of hyperglycemia [23], with the reason being that hyperglycemia in vivo could produce free radicals and generate oxidative stress [23]. However, the exact mechanisms causing reduced PGC-1α expression brought on by hyperglycemia are largely unknown.

PGC-1α activity is influenced by both posttranslational modifications and gene expression levels [10]. It is important to note that the altered AMPK/SIRT1 pathways have been linked to diabetes and have been proposed to explain why PGC-1α activity is reduced [41, 42] (see Figure 1). AMPK phosphorylation stimulates the production and activity of PGC-1α [41]. SIRT1 deacetylates and activates PGC-1α, which prevents mitochondrial biogenesis [42]. An increasing body of research has discovered that hyperglycemia may affect AMPK activity and SIRT1 expression and that the severity of diabetes is negatively connected with AMPK/SIRT1 activity [11, 13, 36, 38]. Furthermore, when subjected to chronic hyperglycemia in diabetes, low AMPK activity and SIRT1 expression levels may decrease PGC-1α expression and activity [11, 13, 36, 38, 42]. Additionally, the animals with the podocyte-specific deletion of SIRT1 showed reduced PGC-1α expression and activity, as well as elevated albuminuria and mitochondrial damage [43]. Therefore, a decrease in PGC-1α activity and mitochondrial dysfunction in the pathophysiology of diabetes-related renal impairment may be attributed to changes in the AMPK/SIRT1 pathways.

3.2.2. Inhibition of Endogenous PGC-1α via SGLT2-Dependent Elevation of Cytoplasmic Sodium and Protons under Hyperglycemic Conditions. It has been noted that hyperglycemia lowered glucagon secretion by SGLT2-dependent increase of intracellular sodium and protons, resulting in decreased mitochondrial biogenesis and ATP generation in α cells [44]. Other SGLT2-expressing cells from hyperglycemic animals, such as renal tubular cells and cardiomyocytes, have also been found to exhibit intracellular sodium and proton buildup phenomena [44–46]. In contrast, SGLT2 inhibitors decreased cytosolic sodium and protons indirectly by activating the sodium-proton exchanger and sodium-potassium ATPase in diabetic experimental models [44–46]. This suggests that SGLT2-dependent cytosolic sodium and proton reduction in renal tubular cells may be the mechanism by which SGLT2 inhibitors protect renal function in type 2 diabetes [44–46]. Altogether, these findings suggest that hyperglycemia increases cytoplasmic sodium and protons as well as decreases mitochondrial biogenesis and ATP production via SGLT2, which further indicates that hyperglycemia-induced SGLT2-dependent elevation of cytoplasmic sodium and protons could be a new pathogenesis for diabetic nephropathy [44–46].

As mentioned above, the primary aspect of diabetes that causes reduced PGC-1α expression is hyperglycemia [10–15, 23]. In addition, type 2 diabetes is characterized by both decreased PGC-1α function and increased SGLT2 activity in the diabetic kidney [47]. Furthermore, it has been shown in experimental models of diabetes that elevation of SGLT2 activity brought on by hyperglycemia increases cytosolic proton, sodium, and sodium-proton exchanger activity [44–46]. In contrast, SGLT2 inhibitors raise PGC-1α expression and mitochondrial biogenesis in diabetic renal tubular cells while decreasing cytosolic sodium and proton levels [44, 45, 47–49]. We hypothesize that the SGLT2-dependent rise of cytoplasmic sodium and proton could result in a reduction in PGC-1α expression in diabetic renal cells since SGLT2 inhibitors have the ability to control cytosolic sodium and proton and PGC-1α expression in renal cells of diabetic patients [44, 45, 47–49] (see Figure 1). In short, persistent hyperglycemia causes SGLT2 to be overloaded, which causes an excess of sodium and glucose to be transported and, as a result, an accumulation of cellular Na⁺. The sodium-proton exchanger activity is reduced in response to the rise in intracellular Na⁺, which leads to a buildup of cellular H⁺. As a consequence, acidosis develops as the cytosolic pH values drop. At the same time, insufficient ATP generation prevents cells from maintaining the Na⁺/K⁺-ATPase activity. These pathways contribute to the decrease of PGC-1α levels, which ultimately results in excessive ROS generation and mitochondrial oxidative stress. However, the exact mechanisms underlying the association between the low expression of PGC-1α in diabetic renal cells and the SGLT2-dependent rise of cytoplasmic sodium and protons remain unknown and require further investigation.

Taken together, these findings suggest that SGLT2-dependent elevation of intracellular sodium and protons might act as a potential mediator of hyperglycemia-inhibited PGC-1α expression in diabetic nephropathy.

3.3. Endogenous PGC-1α Induced by SGLT2 Inhibitors Protects Diabetic Nephropathy. The mechanism underlying the positive effect of SGLT2 inhibitors on diabetes-related renal impairment has recently been found to be that they regulate the hyperglycemia-induced PGC-1α expression in various cells [47–49] (see Figure 2). According to Guo et al., marin may be able to inhibit the development of diabetic nephropathy and boost PGC-1α expression in high glucose-treated HK-2 cells and the renal tissue of db/db mice through inhibiting the expression of renal SGLT2 [48]. In addition, dapagliflozin, an SGLT2 inhibitor, partially reversed the downregulation of PGC-1α expression brought on by hyperglycemia in HK-2 cells, in mouse primary renal proximal tubule cells, and in the renal cortex of hyperglycemic mice fed a high-fat diet [49]. Furthermore, SGLT2 gene knockdown with siRNA resulted in an increase in PGC-1α expression in HK-2 cells [49]. Moreover, SGLT2 inhibitors reduce the amount of Na⁺ and H⁺ that accumulates within cells [44], which raises intracellular PGC-1α levels and promotes mitochondrial biogenesis and ATP production.

The low PGC-1α levels were also significantly increased by the SGLT2 inhibitors empagliflozin and canagliflozin in
the cardiomyocytes and adipocytes of high-fat diet/streptozotocin-induced diabetic mice and rats [50–53], which was consistent with the effect of SGLT2 inhibitors to reverse hyperglycemia-induced downregulation of PGC-1α expression in the kidney. Furthermore, in obese mice, the SGLT2 inhibitor dapagliflozin increased endothelial PGC-1 expression and mitochondrial biosynthesis [54]. In vitro experiments using high glucose- or palmitic acid-induced human umbilical vein endothelial cells revealed that the SGLT2 inhibitor dapagliflozin boosted PGC-1α expression and reduced ROS [54, 55]. All of these findings point to the possibility that SGLT2 inhibitors promote PGC-1α expression and activity, which in turn might boost mitochondrial biogenesis and ATP production to protect diabetic nephropathy.

4. Conclusions

In summary, the review may reveal yet another potential mediator of the lower PGC-1α expression levels brought on by hyperglycemia in diabetics. In short, the SGLT2-dependent rise of cytosolic sodium and protons caused by
hyperglycemia is the cause of the decreased PGC-1α expression in diabetic patients. It will demonstrate a brand-new etiology of mitochondrial malfunction brought on by hyperglycemia in diabetic renal impairment. Additionally, this theory might eventually shed light on a novel etiology of diabetes-related renal impairment as well as the mechanism underlying SGLT2 inhibitors’ positive effects on this condition. Therefore, it should be considered that SGLT2 inhibitors are an effective treatment approach for lowering diabetes-related kidney disease.

**Abbreviations**

DN: Diabetic nephropathy  
FoxO1: Fork head box O1  
HOMA-IR: Homeostasis model assessment-insulin resistance  
IGT: Impaired glucose tolerance  
LDH: Lactate dehydrogenase  
IL-6: Interleukin-6  
TNF-α: Tumor necrosis factor-α  
PGC-1α: Peroxisome proliferator-activated receptor gamma coactivator 1-alpha  
HFD: High-fat diet  
DM: Diabetes mellitus  
ROS: Reactive oxygen species  
FFAs: Free fatty acids.

**Conflicts of Interest**

The authors declare that they have no competing interests.

**Authors’ Contributions**

FP, ZZ, and SY wrote and edited the manuscript. SY, WY, and WL researched the data. ZZ and FP reviewed the manuscript. All authors read and approved the final manuscript. Yuqing She, Mei Yu, and Liang Wang are co-first authors.

**Acknowledgments**

This work was supported by the Youth Project of Natural Scientific Fund of Nanjing University of Chinese Medicine (No. NZY180313792) and Technology Project of Jiangsu Provincial Administration of Traditional Chinese Medicine (No. YB2020087).

**References**

[1] M. Roden and G. I. Shulman, “The integrative biology of type 2 diabetes,” *Nature*, vol. 576, no. 7785, pp. 51–60, 2019.

[2] M. Brownlee, “Biochemistry and molecular cell biology of diabetic complications,” *Nature*, vol. 414, no. 6865, pp. 813–820, 2001.

[3] X. Wang, J. Li, L. Huo et al., “Clinical characteristics of diabetic nephropathy in patients with type 2 diabetes mellitus manifesting heavy proteinuria: a retrospective analysis of 220 cases,” *Diabetes Research and Clinical Practice*, vol. 157, article 107874, 2019.

[4] G. Schernthaner and G. H. Schernthaner, “Diabetic nephropathy: new approaches for improving glycemic control and reducing risk,” *Journal of Nephrology*, vol. 26, no. 6, pp. 975–985, 2013.

[5] S. I. Taylor, Z. S. Yazdi, and A. L. Beitshees, “Pharmacological treatment of hyperglycemia in type 2 diabetes,” *The Journal of Clinical Investigation*, vol. 131, no. 2, article e142243, 2021.

[6] K. Sharma, B. Karl, A. V. Mathew et al., “Metabolomics reveals signature of mitochondrial dysfunction in diabetic kidney disease,” *Journal of the American Society of Nephrology*, vol. 24, no. 11, pp. 1901–1912, 2013.

[7] J. M. Forbes and D. R. Thorburn, “Mitochondrial dysfunction in diabetic kidney disease,” *Nature Reviews. Nephrology*, vol. 14, no. 5, pp. 291–312, 2018.

[8] M. T. Tran, Z. K. Zsengeller, A. H. Berg et al., “PGC1α drives NAD biosynthesis linking oxidative metabolism to renal protection,” *Nature*, vol. 531, no. 7595, pp. 528–532, 2016.

[9] T. Wenz, “Regulation of mitochondrial biogenesis and PGC-1α under cellular stress,” *Mitochondrion*, vol. 13, no. 2, pp. 134–142, 2013.

[10] M. Fontecha-Barruso, D. Martin-Sanchez, J. M. Martinez-Moreno et al., “The role of PGC-1α and mitochondrial biogenesis in kidney diseases,” *Biomolecules*, vol. 10, no. 2, p. 347, 2020.

[11] Q. Wang, B. Zhao, J. Zhang et al., “Faster lipid β-oxidation rate by acetyl-CoA carboxylase 2 inhibition alleviates high-glucose-induced insulin resistance via SIRT1/PGC-1α in human podocytes,” *Journal of Biochemical and Molecular Toxicology*, vol. 35, no. 7, article e22797, 2021.

[12] Y. Yuan, L. Yuan, L. Li et al., “Mitochondrial transfer from mesenchymal stem cells to macrophages restricts inflammation and alleviates kidney injury in diabetic nephropathy mice via PGC-1α activation,” *Stem Cells*, vol. 39, no. 7, pp. 913–928, 2021.

[13] H. Xue, P. Li, Y. Luo et al., “Salidroside stimulates the Sirt 1/PGC-1α axis and ameliorates diabetic nephropathy in mice,” *Phytomedicine*, vol. 54, pp. 240–247, 2019.

[14] X. Xu, N. Zheng, Z. Chen, W. Huang, T. Liang, and H. Kuang, “Puerarin, isolated from Pueraria lobata (Willd.), protects against diabetic nephropathy by attenuating oxidative stress,” *Gene*, vol. 591, no. 2, pp. 411–416, 2016.

[15] T. Imasawa, E. Obre, N. Bellance et al., “High glucose reprograms human podocyte energy metabolism during differentiation and diabetic nephropathy,” *The FASEB Journal*, vol. 31, no. 1, pp. 294–307, 2017.

[16] P. Puigserver, Z. Wu, C. W. Park, R. Graves, M. Wright, and B. M. Spiegelman, “A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis,” *Cell*, vol. 92, no. 6, pp. 829–839, 1998.

[17] Z. Wu, P. Puigserver, U. Andersson et al., “Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1,” *Cell*, vol. 98, no. 1, pp. 115–124, 1999.

[18] P. Puigserver, G. Adelmant, Z. Wu et al., “Activation of PPAR-gamma coactivator-1 through transcription factor docking,” *Science*, vol. 286, no. 5443, pp. 1368–1371, 1999.

[19] S. Da Cruz, P. A. Parone, V. S. Lopes et al., “Elevated PGC-1α activity sustains mitochondrial biogenesis and muscle function without extending survival in a mouse model of...”
inherited ALS,” *Cell Metabolism*, vol. 15, no. 5, pp. 778–786, 2012.

[20] Z. Arany, H. He, J. Lin et al., “Transcriptional coactivator PGC-1α controls the energy state and contractile function of cardiac muscle,” *Cell Metabolism*, vol. 1, no. 4, pp. 259–271, 2005.

[21] K. A. Rasbach and R. G. Schnellmann, “PGC-1α overexpression promotes recovery from mitochondrial dysfunction and cell injury,” *Biochemical and Biophysical Research Communications*, vol. 355, no. 3, pp. 734–739, 2007.

[22] J. St-Pierre, S. Drori, M. Uldry et al., “Suppression of reactive oxygen species and neurodegeneration by the PGC-1α transcriptional coactivators,” *Cell*, vol. 127, no. 2, pp. 397–408, 2006.

[23] K. Guo, J. Lu, Y. Huang et al., “Protective role of PGC-1α in diabetic nephropathy is associated with the inhibition of ROS through mitochondrial dynamic remodeling,” *PLoS One*, vol. 10, no. 4, article e0125176, 2015.

[24] D. Marmolino, M. Manto, F. Acquaviva et al., “PGC-1α regulates down-regulation affects the antioxidant response in Friedreich’s ataxia,” *PLoS One*, vol. 5, no. 4, article e001025, 2010.

[25] I. Valle, A. Alvarez-Barrientos, E. Arza, S. Lamas, and M. Monsalve, “PGC-1α regulates the mitochondrial antioxidant defense system in vascular endothelial cells,” *Cardiovascular Research*, vol. 66, no. 3, pp. 562–573, 2005.

[26] I. Suntar, A. Sureda, T. Belwal et al., “Natural products, PGC-1α, and Duchenne muscular dystrophy,” *Acta Pharmaceutica Sinica B*, vol. 10, no. 5, pp. 734–745, 2020.

[27] J. A. Baur, K. J. Pearson, N. L. Price et al., “Resveratrol improves health and survival of mice on a high-calorie diet,” *Nature*, vol. 444, no. 7117, pp. 337–342, 2006.

[28] M. Lagouge, C. Argmann, Z. Gerhart-Hines et al., “Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1α,” *Cell*, vol. 127, no. 6, pp. 1109–1122, 2006.

[29] S. Yuan, X. Liu, X. Zhu et al., “The role of TLR4 on PGC-1α-mediated oxidative stress in tubular cell in diabetic kidney disease,” *Oxidative Medicine and Cellular Longevity*, vol. 2018, Article ID 6296802, 14 pages, 2018.

[30] L. Zhang, J. Liu, F. Zhou, W. Wang, and N. Chen, “PGC-1α ameliorates kidney fibrosis in mice with diabetic kidney disease through an antioxidative mechanism,” *Molecular Medicine Reports*, vol. 17, no. 3, pp. 4490–4498, 2018.

[31] L. Xiao, X. Zhu, S. Yang et al., “Rap1 ameliorates renal tubular injury in diabetic nephropathy,” *Diabetes*, vol. 63, no. 4, pp. 1366–1380, 2014.

[32] L. Wu, Q. Wang, F. Guo et al., “Activation of FoxO1/PGC-1α prevents mitochondrial dysfunction and ameliorates mesangial cell injury in diabetic rats,” *Molecular and Cellular Endocrinology*, vol. 413, pp. 1–12, 2015.

[33] G. Al-Kafaji, M. A. Sabry, and C. Skrypnyk, “Time-course effect of high-glucose-induced reactive oxygen species on mitochondrial biogenesis and function in human renal mesangial cells,” *Cell Biology International*, vol. 40, no. 1, pp. 36–48, 2016.

[34] D. Zhou, M. Zhou, Z. Wang et al., “PGRN acts as a novel regulator of mitochondrial homeostasis by facilitating mitochondophy and mitochondrial biogenesis to prevent podocyte injury in diabetic nephropathy,” *Cell Death & Disease*, vol. 10, no. 7, p. 524, 2019.

[35] X. Qin, M. Jiang, Y. Zhao et al., “Berberine protects against diabetic kidney disease via promoting PGC-1α-regulated mitochondrial energy homeostasis,” *British Journal of Pharmacology*, vol. 177, no. 16, pp. 3646–3661, 2020.

[36] T. Zhang, Y. Chi, Y. Kang et al., “Resveratrol ameliorates podocyte damage in diabetic mice via SIRT1/PGC-1α-mediated attenuation of mitochondrial oxidative stress,” *Journal of Cellular Physiology*, vol. 234, no. 4, pp. 5033–5043, 2019.

[37] H. S. Park, J. H. Lim, M. Y. Kim et al., “Resveratrol increases AdipoR1 and AdipoR2 expression in type 2 diabetic nephropathy,” *Journal of Translational Medicine*, vol. 14, no. 1, p. 176, 2016.

[38] M. Y. Kim, J. H. Lim, H. H. Yoon et al., “Resveratrol prevents renal lipotoxicity and inhibits mesangial cell glucotoxicity in a manner dependent on the AMPK-SIRT1-PGC1α axis in db/db mice,” *Diabetologia*, vol. 56, no. 1, pp. 204–217, 2013.

[39] W. Qi, H. A. Keenan, Q. Li et al., “Pyruvate kinase M2 activation may protect against the progression of diabetic glomerular pathology and mitochondrial dysfunction,” *Nature Medicine*, vol. 23, no. 6, pp. 753–762, 2017.

[40] J. Long, S. S. Badal, Z. Ye et al., “Long noncoding RNA Tug1 regulates mitochondrial bioenergetics in diabetic nephropathy,” *The Journal of Clinical Investigation*, vol. 126, no. 11, pp. 4205–4218, 2016.

[41] S. Jäger, C. Handschin, J. St-Pierre, and B. M. Spiegelman, “AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1α,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 104, no. 29, pp. 12017–12022, 2007.

[42] J. T. Rodgers, C. Lerin, W. Haas, S. P. Gygi, B. M. Spiegelman, and P. Puigserver, “Nutrient control of glucose homeostasis through a complex of PGC-1α and SIRT1,” *Nature*, vol. 434, no. 7029, pp. 113–118, 2005.

[43] P. Y. Chuang, W. Cai, X. Li et al., “Reduction in podocyte SIRT1 accelerates kidney injury in aging mice,” *American Journal of Physiology. Renal Physiology*, vol. 313, no. 3, pp. F621–F628, 2017.

[44] J. G. Knudsen, A. Hamilton, R. Ramracheya et al., “Dysregulation of glucagon secretion by hyperglycemia-induced sodium-dependent reduction of ATP production,” *Cell Metabolism*, vol. 29, no. 2, pp. 430–442.e4, 2019.

[45] R. Z. Alicic, J. J. Neumiller, E. J. Johnson, B. Dieter, and K. R. Cherney, “Role of ketogenic starvation sensors in mediating the renal protective effect of SGLT2 inhibitors in type 2 diabetes,” *Kidney International*, vol. 94, no. 1, pp. 26–39, 2018.

[46] M. Packer, “Renoprotective effects of sodium-glucose co-transporter-2 inhibitors,” *Kidney International*, vol. 94, no. 1, pp. 26–39, 2018.

[47] Y. Guo, Z. Ran, Y. Zhang et al., “Marine ameliorates diabetic nephropathy by inhibiting renal sodium glucose transporter 2 and activating the AMPK signaling pathway in db/db mice and high glucose-treated HK-2 cells,” *Biomedicine & Pharmacotherapy*, vol. 131, article 110684, 2020.

[48] J. H. Kim, H. Y. Ko, H. J. Wang, H. Lee, M. Yun, and E. S. Kang, “Effect of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on gluconeogenesis in proximal renal
tubules,” *Diabetes, Obesity & Metabolism*, vol. 22, no. 3, pp. 373–382, 2020.

[50] Q. Shao, L. Meng, S. Lee et al., “Empagliflozin, a sodium glucose co-transporter-2 inhibitor, alleviates atrial remodeling and improves mitochondrial function in high-fat diet/streptozotocin-induced diabetic rats,” *Cardiovascular Diabetology*, vol. 18, no. 1, p. 165, 2019.

[51] D. Wei, L. Liao, H. Wang, W. Zhang, T. Wang, and Z. Xu, “Canagliflozin ameliorates obesity by improving mitochondrial function and fatty acid oxidation via PPARα in vivo and in vitro,” *Life Sciences*, vol. 247, article 117414, 2020.

[52] X. Yang, Q. Liu, Y. Li et al., “The diabetes medication canagliflozin promotes mitochondrial remodelling of adipocyte via the AMPK-Sirt1-Pgc-1α signalling pathway,” *Adipocytes*, vol. 9, no. 1, pp. 484–494, 2020.

[53] M. Waldman, K. Cohen, D. Yadin et al., “Regulation of diabetic cardiomyopathy by caloric restriction is mediated by intracellular signaling pathways involving SIRT1 and PGC-1α,” *Cardiovascular Diabetology*, vol. 17, no. 1, p. 111, 2018.

[54] L. He, Y. Li, D. Zhang, H. Song, D. Xu, and Z. Song, “Dapagliflozin improves endothelial cell dysfunction by regulating mitochondrial production via the SIRT1/PGC-1α pathway in obese mice,” *Biochemical and Biophysical Research Communications*, vol. 615, pp. 123–130, 2022.

[55] Y. Faridvand, H. Kazemzadeh, V. Vahedian et al., “Dapagliflozin attenuates high glucose-induced endothelial cell apoptosis and inflammation through AMPK/SIRT1 activation,” *Clinical and Experimental Pharmacology & Physiology*, vol. 49, no. 6, pp. 643–651, 2022.